Loading...
•
Dec 31, 2023
Theravance Q4 2023 Earnings Report
Announced financial and operational results for the fourth quarter of 2023 and full-year ended December 31, 2023.
Key Takeaways
Theravance Biopharma reported strong performance in 2023, achieving financial objectives in the fourth quarter and exceeding the annual goal for YUPELRI hospital growth. The company looks forward to continuing YUPELRI net sales growth in 2024 and completing enrollment in the CYPRESS study in the second half of the year.
Theravance team delivered a strong performance in 2023.
Achieved financial objectives in the fourth quarter.
Exceeded aggressive annual goal for YUPELRI hospital growth.
Completing enrollment in the CYPRESS study in the second half of this year.
Revenue by Segment
Forward Guidance
Theravance Biopharma expects to continue YUPELRI net sales growth in 2024 and complete enrollment in the CYPRESS study in the second half of this year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...